Role of genetics in prognostication in myeloma

Carrasco, 2006, High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients, Cancer Cell, 9, 313, 10.1016/j.ccr.2006.03.019 Walker, 2006, Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma, Blood, 108, 1733, 10.1182/blood-2006-02-005496 Dewald, 1985, The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia or amyloidosis, Blood, 66, 380, 10.1182/blood.V66.2.380.380 Weh, 1993, Karyotype in multiple myeloma and plasma cell leukemia, European Journal of Cancer, 29A, 1269, 10.1016/0959-8049(93)90071-M Sawyer, 1995, Cytogenetic findings in 200 patients with multiple myeloma, Cancer Genetics and Cytogenetics, 82, 41, 10.1016/0165-4608(94)00284-I Laï, 1995, Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis, Blood, 85, 2490, 10.1182/blood.V85.9.2490.bloodjournal8592490 Calasanz, 1997, Cytogenetic analysis of 280 patients with muliple myeloma and related disorders: primary breakpoints and clinical correlations, Genes Chromosomes & Cancer, 18, 84, 10.1002/(SICI)1098-2264(199702)18:2<84::AID-GCC2>3.0.CO;2-X Smadja, 2001, Hypodiploidy is a major prognostic factor in multiple myeloma, Blood, 98, 2229, 10.1182/blood.V98.7.2229 Drach, 1995, Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization, Cancer Research, 55, 3854 Drach, 1995, Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance, Blood, 86, 3915, 10.1182/blood.V86.10.3915.bloodjournal86103915 Zandecki, 1997, Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition, Blood, 90, 3682, 10.1182/blood.V90.9.3682 Nishida, 1997, The Ig heavy chain is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization, Blood, 90, 526, 10.1182/blood.V90.2.526 Fonseca, 2003, The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma, Blood, 102, 2562, 10.1182/blood-2003-02-0493 Debes-Marun, 2003, Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma, Leukemia, 17, 427, 10.1038/sj.leu.2402797 Chng, 2006, Ploidy status rarely changes in myeloma patients at disease progression, Leukemia Research, 30, 266, 10.1016/j.leukres.2005.07.004 Wuillème, 2005, Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma, Leukemia, 19, 275, 10.1038/sj.leu.2403586 Chng, 2005, A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS, Blood, 106, 2156, 10.1182/blood-2005-02-0761 Avet-Loiseau, 2007, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome, Blood, 109, 3489, 10.1182/blood-2006-08-040410 Avet-Loiseau, 1999, Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma, Blood, 94, 2583, 10.1182/blood.V94.8.2583.420a05_2583_2589 Zojer, 2000, Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization, Blood, 95, 1925, 10.1182/blood.V95.6.1925 Desikan, 2000, Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities, Blood, 95, 4008, 10.1182/blood.V95.12.4008 Facon, 2001, Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy, Blood, 97, 1566, 10.1182/blood.V97.6.1566 Fonseca, 2002, Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study, Cancer Research, 62, 715 Zhan, 2003, Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development, Blood, 101, 1128, 10.1182/blood-2002-06-1737 Agnelli, 2007, Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma, Haematologica, 92, 56, 10.3324/haematol.10414 Tricot, 1995, Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities, Blood, 86, 4250, 10.1182/blood.V86.11.4250.bloodjournal86114250 Shaughnessy, 2003, Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II, British Journal of Haematology, 120, 44, 10.1046/j.1365-2141.2003.03948.x Chiecchio L, Protheroe RK, Ibrahim AH et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia20:1610–1617. Laï, 1998, Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant, Cancer Genetics and Cytogenetics, 104, 133, 10.1016/S0165-4608(97)00469-X Fonseca, 1998, Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases, British Journal of Haematology, 101, 296, 10.1046/j.1365-2141.1998.00700.x Bergsagel, 1996, Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma, Proceedings of the National Academy of Sciences of the United States of America, 93, 13931, 10.1073/pnas.93.24.13931 Avet-Loiseau, 2002, Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features and clinical presentation, Blood, 99, 2185, 10.1182/blood.V99.6.2185 Fonseca, 2004, Genetics and cytogeneticsof multiple myeloma: a workshop report, Cancer Research, 64, 1546, 10.1158/0008-5472.CAN-03-2876 Chesi, 1996, Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines, Blood, 88, 674, 10.1182/blood.V88.2.674.bloodjournal882674 Janssen, 2000, Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32), Blood, 95, 2691 Fonseca, 2002, Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients, Blood, 99, 3735, 10.1182/blood.V99.10.3735 Garand, 2003, t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma, Leukemia, 17, 2032, 10.1038/sj.leu.2403091 Robillard, 2003, CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma, Blood, 102, 1070, 10.1182/blood-2002-11-3333 Moreau, 2002, Recurrent 14q32 translocations determine the prognosis of multiple myeloma especially in patients receiving intensive chemotherapy, Blood, 100, 1579, 10.1182/blood-2002-03-0749 Gertz, 2005, Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy, Blood, 106, 2837, 10.1182/blood-2005-04-1411 Chesi, 1997, Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3, Nature Genetics, 16, 260, 10.1038/ng0797-260 Chesi, 1998, The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts, Blood, 92, 3025, 10.1182/blood.V92.9.3025 Stec, 1998, WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a drosophila dysmorphy gene maps in the Wolf-Hirschorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma, Human Molecular Genetics, 7, 1071, 10.1093/hmg/7.7.1071 Plowright, 2000, Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis, Blood, 9, 992, 10.1182/blood.V95.3.992.003k29_992_998 Li, 2001, The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells, Blood, 97, 2413, 10.1182/blood.V97.8.2413 Keats, 2003, In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression, Blood, 101, 1520, 10.1182/blood-2002-06-1675 Santra, 2003, A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript, Blood, 101, 2374, 10.1182/blood-2002-09-2801 Chesi, 1998, Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma, Blood, 91, 4457, 10.1182/blood.V91.12.4457 Hurt, 2004, Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma, Cancer Cell, 5, 191, 10.1016/S1535-6108(04)00019-4 Hanamura, 2001, Ectopic expression of MAFB gene in human myeloma cells carrying the t(14;20)(q32;q11) chromosomal translocations, Japanese Journal of Cancer Research, 92, 638, 10.1111/j.1349-7006.2001.tb01142.x Drach, 1998, Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy, Blood, 92, 802, 10.1182/blood.V92.3.802 Chang, 2005, p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation, Blood, 105, 358, 10.1182/blood-2004-04-1363 Portier, 1992, P53 and RAS gene mutations in multiple myeloma, Oncogene, 7, 2539 Preudhomme, 1992, Rare occurrence of P53 gene mutations in multiple myeloma, British Journal of Haematology, 81, 440, 10.1111/j.1365-2141.1992.tb08253.x Chng, 2007, Clinical significance of TP53 mutation in myeloma, Leukemia, 21, 582, 10.1038/sj.leu.2404524 Hanamura, 2006, Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation, Blood, 108, 1724, 10.1182/blood-2006-03-009910 Sawyer, 2005, Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q, Genes Chromosomes & Cancer, 42, 95, 10.1002/gcc.20109 Fonseca, 2006, Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma, Leukemia, 20, 2034, 10.1038/sj.leu.2404403 Shaughnessy, 2007, A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, 109, 2276, 10.1182/blood-2006-07-038430 Jagannath, 2007, Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials, Leukemia, 21, 151, 10.1038/sj.leu.2404442 Sagaster, 2007, Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion, Leukemia, 21, 164, 10.1038/sj.leu.2404459